LEUKEMIA & LYMPHOMA

Note: The following journal information is for reference only. Please check the journal website for updated information prior to submission.

Journal Title

LEUKEMIA & LYMPHOMA

LEUKEMIA LYMPHOMA

ISSN / eISSN

1042-8194 / 1029-2403

Aims and Scope

Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor

Subject Area

HEMATOLOGY

ONCOLOGY

CiteScore

4.00

View Trend

CiteScore Ranking

Category	Quartile	Rank
Medicine - Hematology	Q3	#67/129
Medicine - Oncology	Q3	#200/366
Medicine - Cancer Research	Q3	#151/214

Web of Science Core Collection

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

Category (Journal Citation Reports 2023)	Quartile
HEMATOLOGY - SCIE	Q3
ONCOLOGY - SCIE	Q3

H-index

Country/Area of Publication

ENGLAND

Publisher

Informa Healthcare

Publication Frequency

Monthly

Year Publication Started

1989

Annual Article Volume

263

Open Access

Contact

TAYLOR & FRANCIS LTD, 4 PARK SQUARE, MILTON PARK, ABINGDON, ENGLAND, OXON, OX14 4RN

Popular journals in the same field
Recent articles

Primary central nervous system lymphoma in children - a rare but serious disease with good prognosis from a single center in China: (2023) Yanlong Duan, Huixia Gao, Chunju Zhou, Ling Jin, Jing Yang, Shuang Huang, Ningning Zhang, Meng Zhang, Xueliang Yang, Yonghong Zhang, Tianyou Wang

Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’: (2023) Dahniel Sastow, Joshua Tatarian, Christian Salib, Tara L. Lin, Douglas Tremblay

Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group: (2023) Oktawia Sośnia, Katarzyna Pruszczyk, Michał Danecki, Ewa Wąsik-Szczepanek, Jagoda Tryc-Szponder, Elżbieta Iskierka-Jażdżewska, Alan Majeranowski, Hele...

Comprehensive genomic profiling reveals molecular subsets of ASXL1 -mutated myeloid neoplasms: (2023) Steven M. Johnson, James Haberberger, Jonathan Galeotti, Lori Ramkissoon, Catherine C. Coombs, Daniel R. Richardson, Matthew C. Foster, Daniel Duncan,...

Blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives: (2023) John L. Frater

Clinical characteristics, treatment patterns, and outcomes among African American and White patients with multiple myeloma in the United States: (2023) Ashley Saunders, Samantha Slaff, Krishnaveni Subbiah, Tao Gu, Kwan-Keat Ang, Michelle Alyssa Quan, Aaron Seth Rosenberg

RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL: (2023) Hidehiro Itonaga, Takeharu Kato, Yasushi Sawayama, Shinichi Katsuoka, Takafumi Furumoto, Nariyoshi Matsumoto, Daisuke Sasaki, Yuichi Yamada, Miki Hash...

Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis: (2023) Amélie Trinquand, David R. Betts, Shauna Harte, Aoife Sills, Sean Rooney, Neil Barrett, Lorna Storey, Andrea Malone, Aengus O’Marcaigh, Owen P. Smith

Re: exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma: (2023) Paul J. Villeneuve, Shelley A. Harris

MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis: (2023) Neslihan Meriç, Esra Albayrak, Zafer Gülbaş, Fatih Kocabaş

Verified Reviews

Note: Verified reviews are sourced from across review platforms and social media globally.

Notification of format change one week after submission on October 9th. Major revisions on November 3rd. Revised version submitted on December 6th. Minor revisions made on the same day as December 16th. Acceptance on December 20th. Not sure when it will be available online. The reviewer is quite diligent and professional.

2021-12-25

View All Reviews

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More